Statins are the foundation of cardiovascular risk reduction, yet up to 10% of patients experience statin-associated muscle symptoms (SAMS) that prevent them from taking effective doses. To address this clinical challenge, researchers developed bempedoic acid (marketed as Nexletol), which was approved by the FDA in 2020. As a novel oral non-statin agent, bempedoic acid offers a unique mechanism that target the cholesterol pathway in the liver while completely sparing skeletal muscle, making it a key therapy for patients with statin intolerance.
The Liver-Specific Mechanism: Sparing the Muscles
Bempedoic acid is an inhibitor of adenosine triphosphate-citrate lyase (ACL), an enzyme that acts upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. By blocking ACL, bempedoic acid prevents the conversion of citrate to acetyl-CoA, reducing the building blocks available for cholesterol synthesis. Similar to statins, this intracellular depletion triggers the liver to upregulate LDL receptors, increasing the clearance of LDL-C from the circulation.
What makes bempedoic acid unique is its pharmacokinetics as a prodrug. Bempedoic acid is administered in an inactive form. To become active, it requires the addition of a coenzyme by the enzyme very long-chain acyl-CoA synthetase-1 (ACSVL1). ACSVL1 is highly active in liver cells (hepatocytes) but is entirely absent in skeletal muscle tissue. Consequently, bempedoic acid cannot be activated in muscle cells. This liver-specific activation explains why it does not cause the muscle pain, weakness, or cramping associated with statins, which block HMG-CoA reductase directly in both liver and muscle tissue, as explained in Managing Statin Muscle Symptoms.
Clinical Efficacy and Fixed-Dose Combinations
As monotherapy, bempedoic acid 180 mg daily reduces LDL-C by approximately 15% to 25%. However, its clinical utility is significantly enhanced when paired with ezetimibe. A fixed-dose combination pill containing bempedoic acid 180 mg and ezetimibe 10 mg (marketed as Nexlizet) is available, utilizing dual mechanisms to achieve a 35% to 40% reduction in LDL-C. This combination provides a powerful oral non-statin regimen for patients who cannot tolerate statins or who need additional lowering on top of their tolerated statin dose, as described in Ezetimibe and LDL Reduction.
Cardiovascular Outcomes: The CLEAR Outcomes Trial
The clinical benefits of bempedoic acid were validated by the landmark CLEAR Outcomes trial (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen), published in 2023. The trial enrolled over 13,900 statin-intolerant patients with, or at high risk for, cardiovascular disease. Participants were randomized to receive bempedoic acid 180 mg daily or a placebo.
Over a median follow-up of 3.4 years, bempedoic acid reduced LDL-C by 21% and significantly reduced high-sensitivity C-reactive protein (hs-CRP) by 22%, indicating an anti-inflammatory effect. Most importantly, bempedoic acid reduced the primary composite endpoint of major adverse cardiovascular events (MACE)—cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization—by 13%. This trial confirmed that bempedoic acid not only lowers lipid levels but also reduces actual clinical events in patients who cannot tolerate statins.
Side Effects and Clinical Considerations
While bempedoic acid successfully avoids muscle side effects, it is associated with other specific adverse effects that clinicians must monitor:
- Hyperuricemia and Gout: Bempedoic acid competes with uric acid for renal excretion through organic anion transporters (specifically OAT2). This leads to a mild increase in serum uric acid levels, which can trigger acute gout flare-ups in susceptible individuals. In the clinical trials, gout occurred in about 3% of patients taking bempedoic acid compared to 1% in the placebo group.
- Tendon Rupture: Although rare (occurring in less than 0.5% of patients), bempedoic acid has been associated with an increased risk of tendon rupture, particularly involving the Achilles tendon, rotator cuff, or biceps. This risk is higher in elderly patients, those taking oral corticosteroids, or those with a history of tendon disorders.
- Mild Kidney Function Changes: Small, reversible increases in blood urea nitrogen (BUN) and creatinine can occur.
💡 💡 Clinical Pearl: Gout and Tendon Risk Screening
Prior to starting bempedoic acid, check the patient’s baseline uric acid levels and ask about a history of gout or tendon injury. For patients with a history of recurrent gout, monitor uric acid periodically and consider alternative agents if levels rise significantly.
💡 Frequently Asked Questions (FAQ)
Q1: If I had severe muscle pain on Lipitor, will I have muscle pain on Nexletol?
A1: It is highly unlikely. Bempedoic acid (Nexletol) is designed to bypass muscle cells entirely because muscle tissue lacks the specific enzyme required to activate the drug. In clinical trials, muscle-related side effects were similar to a placebo.
Q2: Can I take bempedoic acid with a statin?
A2: Yes. Bempedoic acid can be added to low- or moderate-dose statins to help you achieve your LDL-C goals. However, it should not be co-administered with Simvastatin doses greater than 20 mg or Pravastatin doses greater than 40 mg due to potential increases in statin levels.
Q3: How soon will my cholesterol drop after starting Nexletol?
A3: Bempedoic acid works relatively quickly. You can expect to see a significant reduction in your LDL-C levels within 4 weeks of starting the daily medication.
📚 References & Sources
- Nissen, S. E., et al. (2023). Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine.
- Ray, K. K., et al. (2019). Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. New England Journal of Medicine.
- Goldberg, A. C., et al. (2019). Effect of Bempedoic Acid vs Placebo on LDL Cholesterol in Patients with High Cardiovascular Risk receiving Max Tolerated Statins: The CLEAR Wisdom Trial. JAMA.